Sunday 25 August 2019 ,
Sunday 25 August 2019 ,
Latest News
  • Concentrate on your obligations, commitments: Bangladesh to Myanmar
  • Protect migrant workers from middlemen: PM
  • Zia had betrayed Bangabandhu: Quader
  • 2 years of Rohingya influx: 43 murders in camps, 32 killed in gunfights
  • HC orders to remove word ‘Kumari’ from marriage certificate
  • Prepaid metres system ‘unfair’: PMCRC
11 February, 2019 00:00 00 AM

FDA approves Tosymra (sumatriptan) nasal spray for acute treatment of migraine

drugs.com
FDA approves Tosymra (sumatriptan) nasal spray for acute treatment of migraine

Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC recently announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment portfolio. The company is working toward commercialization of this product.

“We are excited about the approval of Tosymra. This approval affirms our ability to develop well-differentiated products to meet the unmet needs of patients with migraine and HCPs treating them,” said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories.

According to Dr. Anil Namboodiripad, PhD, President, Promius Pharma, “Tosymra nasal spray is formulated using a proprietary novel excipient known as Intravail [®] to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action. Independent research shows that 26% to 40% of migraine patients are not optimally controlled with their current treatment.

[1] For patients who suffer from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options. At Promius, we are committed to developing new ways of improving patient experiences. Tosymra is a mist-like nasal spray that acts rapidly and is well tolerated.”

Important patient safety information

Tosymra can cause serious side effects, including: heart attack and other heart problems, which may lead to death.

Stop using Tosymra and get emergency medical help right away if you have any of the following symptoms of a heart attack:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back

severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw

pain or discomfort in your arms, back, neck, jaw, or stomach

shortness of breath with or without chest discomfort

breaking out in a cold sweat

nausea or vomiting

feeling lightheaded

Tosymra is not for people with risk factors for heart disease (high blood pressure, high cholesterol levels, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem.

Do not use Tosymra if you have:

heart problems or a history of heart problems

narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)

uncontrolled high blood pressure

severe liver problems

hemiplegic migraines or basilar migraines. If you are not sure if you have these, ask your healthcare provider

had a stroke, transient ischemic attacks (TIAs), or problems with your blood circulation

taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your healthcare provider if you are not sure if your medicine is listed above

are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.

an allergy to sumatriptan or any of the ingredients in Tosymra.

What are possible side effects of Tosymra?

Tosymra may cause serious side effects including:

changes in color or sensation in your fingers and toes (Raynaud’s syndrome)

stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include: sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever

problems with blood circulation to your legs and feet (peripheral vascular ischemia). Symptoms of peripheral vascular ischemia include: cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in 1 or both legs or feet

Increased blood pressure including a sudden severe increase (hypertensive crisis) even if you have no history of high blood pressure

medication overuse headaches. Some people who use too much migraine medicine, such as Tosymra, for 10 or more days each month may have worse headaches (medication overuse headache).

If your headaches get worse, your healthcare provider may decide to stop your treatment with Tosymra.

serotonin syndrome. Serotonin syndrome is a rare but serious problem that can happen in people using Tosymra, especially if Tosymra is used with anti-depressant medicines called SSRIs or SNRIs.

Call your healthcare provider right away if you have any of the following:

symptoms of serotonin syndrome: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking

hives (itchy bumps); swelling of your tongue, mouth, or throat

seizures have happened in people taking sumatriptan who have never had seizures before

The most common side effects of Tosymra include tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Tosymra. For more information, ask your healthcare provider or pharmacist.

What is Tosymra used for?

Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.

Tosymra is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. Tosymra is not used to treat cluster headaches.

Tosymra is not used to prevent or decrease the number of migraines you have.

It is not known if Tosymra is safe and effective in children under 18 years of age.

 

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Nutrition starts in the embryonic life as the trophoblast cells invade the deciduas digesting and imbibing it. Progesterone secreted during last half…
Overview of nutrition

Overview of nutrition

Nutrition id the process of providing or obtaining the food necessary for health and growth particularly in humans. It is the nourishment of energy and…
Nutritional disorders

Nutritional disorders

John C.M. Brust Nutritional deficiency can adversely affect the nervous system, both centrally and peripherally, leading to problems in thinking and other…
Nutritional status in Bangladesh

Nutritional status in Bangladesh

Rates of malnutrition in Bangladesh are among the highest in the world. More than 54% of preschool-age children, equivalent to more than 9.5 million children,…
Global nutrition targets 2025

Global nutrition targets 2025

Recognizing that accelerated global action is needed to address the pervasive and corrosive problem of the double burden of malnutrition, in 2012 the…
10 facts on nutrition

10 facts on nutrition

Nutrition is a critical part of health and development. Better nutrition is related to improved infant, child and maternal health, stronger immune systems,…
What exactly is a disease?

What exactly is a disease?

DUANE MELLOR There is an ongoing lively debate among healthcare professionals about whether or not obesity is a disease. Differences between those who…
OB/GYNs explain when you should (and shouldn’t) worry about period blood clots

OB/GYNs explain when you should (and shouldn’t) worry about period blood clots

KAITLYN PIRIE Even though blood clots sound scary, they’re usually a good thing. When you experience an injury—say, you accidentally cut yourself—your…
Deadly new fungal superbug is worrying doctors — here's what you need to know

Deadly new fungal superbug is worrying doctors — here's what you need to know

ABBY HAGLAGE Months after health officials in New York, New Jersey and Illinois raised concerns about a new deadly fungal superbug, a study has suggested…
Should you take daily aspirin for your heart?

Should you take daily aspirin for your heart?

LINDSEY KONKEL  Nearly 30 million Americans who are 40 or older—who don’t have cardiovascular disease—take aspirin every day anyway,…
SHARE project of icddr,b launch documentary films on prevention of NCDs

SHARE project of icddr,b launch documentary films on prevention of NCDs

Recently, Strengthening Health, Applying Research Evidence (SHARE) project of icddr,b in collaboration with University College London (UCL), United Kingdom…
Lyme disease: Older white women 'at highest risk'

Lyme disease: Older white women 'at highest risk'

Older women are at most risk of contracting Lyme disease, a study suggests - and parts of southern and south-west England are "hotspots". There…
FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) recently…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting